On October 7, Moderna, Inc. rose 3.01% in regular trading, trading at $193.02 per share with a turnover of $1.126 billion. The stock continued to be supported by expectations of passive fund inflows ahead of its inclusion in the Nasdaq-100 Index before the market opens on October 9.

The catalyst extends beyond index inclusion. Tempus announced an expanded collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene, an individualized cancer therapy being tested with Keytruda. Under the agreement, Tempus will manage tumor tissue and blood sample collection, sequencing, and logistics to support therapy design and manufacturing, reinforcing the commercial pathway for Moderna's oncology pipeline.

Analyst sentiment is mixed. According to FactSet, Moderna holds an average rating of \"hold\" with a mean price target of $116.84. Morgan Stanley recently adjusted its price target to $95 from $89, still well below the current market price, highlighting a significant divergence between passive-inflow-driven valuation and sell-side fundamental assessments.

Moderna, Inc. is a biotechnology company focused on discovering, developing, and commercializing messenger RNA therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases. Its pipeline includes respiratory vaccines, latent vaccines, cancer vaccines, and intratumoral immuno-oncology products, with strategic alliances involving AstraZeneca, Merck, Vertex Pharmaceuticals, and other partners. The company was founded in 2010 and is headquartered in Cambridge, Massachusetts.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)